



Universiteit
Leiden
The Netherlands

Optimizing immunotherapy in locoregional and metastatic urothelial cancer

Dijk, N. van

Citation

Dijk, N. van. (2024, January 16). *Optimizing immunotherapy in locoregional and metastatic urothelial cancer*. Retrieved from <https://hdl.handle.net/1887/3713954>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3713954>

Note: To cite this publication please use the final published version (if applicable).

Optimizing immunotherapy in locoregional and metastatic urothelial cancer

Nick van Dijk

ISBN: 978-94-6361-911-0

Cover design: Nick van Dijk

Lay-out & printing: Optima Grafische Communicatie, Rotterdam | www.ogc.nl

© Nick van Dijk 2023, Utrecht, The Netherlands

All rights reserved. No part of this publication may be reproduced, distributed, stored in a retrieval system, or transmitted in any form or by any means without prior written consent of the author.

Optimizing immunotherapy in locoregional and metastatic urothelial cancer

Proefschrift

ter verkrijging van de graad van doctor
aan de Universiteit van Leiden,
op gezag van de Rector Magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op 16 januari 2024,
klokke 16:15 uur

door

Nick van Dijk
geboren te Hilversum

Promotor

Prof. dr. J.B.A.G. Haanen

Copromotor

Dr. M.S. van der Heijden, NKI-AVL

Promotiecommissie

Prof. dr. C.U. Blank

Prof. dr. C.L. Zuur

Prof. dr. J.L. Boormans, EUR

Dr. B.B.M. Suelmann, UMCU

CONTENTS

| | | |
|--|---|-----|
| Chapter 1 | General introduction and thesis outline | 7 |
| Part I: Checkpoint immunotherapy in metastatic urothelial cancer | | |
| Chapter 2 | Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer | 21 |
| Chapter 3 | Clinical outcome after progressing to frontline and second-line anti-PD-1/PD-L1 in advanced urothelial cancer | 31 |
| Part II: Preoperative checkpoint immunotherapy in urothelial cancer | | |
| Chapter 4 | Preoperative ipilimumab plus nivolumab in locoregionally advanced UC: NABUCCO trial | 51 |
| Chapter 5 | Survival after neoadjuvant/induction combination immunotherapy versus combination platinum-based chemotherapy for stage III urothelial cancer | 87 |
| Part III: Checkpoint immunotherapy biomarkers in urothelial cancer | | |
| Chapter 6 | The tumor immune landscape and architecture of tertiary lymphoid structures in urothelial cancer | 111 |
| Chapter 7 | The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer | 153 |
| Chapter 8 | General discussion and future perspectives | 175 |
| Chapter 9 | Summary Samenvatting | 191 |
| Appendices | | |
| | Curriculum Vitae | 205 |
| | List of publications | 207 |
| | Dankwoord | 209 |